Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics 2024年第一季度GAAP每股收益美元（0.72）超過預期（0.84）
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.84) by 14.29 percent. This is a 17.24 percent increase over losses of $(0.87) per share from the same period last year.
Relmada Therapeutics（納斯達克股票代碼：RLMD）公佈的季度虧損爲每股0.72美元，比分析師共識估計的美元（0.84美元）高出14.29％。這比去年同期每股虧損0.87美元（0.87美元）增長了17.24％。